Avenus announced new oculomotor function and biomarker data for the phase 1 clinical trial of ARV-102, its Parkinson's disease treatment drug.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.